Goldman Sachs
ORKA

Goldman Sachs’s Oruka Therapeutics ORKA Stock Holding History

Goldman Sachs’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Sell
179,439
-67,272
-27% -$4.48M ﹤0.01% 2799
2026
Q1 		$12.1M Buy
246,711
+153,716
+165% +$5.34M ﹤0.01% 2890
2025
Q4 		$2.82M Buy
92,995
+73,220
+370% +$2.04M ﹤0.01% 4274
2025
Q3 		$380K Sell
19,775
-52,474
-73% -$778K ﹤0.01% 5649
2025
Q2 		$810K Sell
72,249
-171,950
-70% -$1.79M ﹤0.01% 4845
2025
Q1 		$2.51M Buy
+244,199
New +$3.05M ﹤0.01% 3963
2021
Q3 		– Sell
-1,160
Closed -$49K – 6565
2021
Q2 		$49K Buy
+1,160
New +$48.4K ﹤0.01% 6069
2021
Q1 		– Sell
-2,525
Closed -$121K – 6402
2020
Q4 		$121K Buy
+2,525
New +$126K ﹤0.01% 5259
2017
Q3 		– Sell
-75
Closed -$39K – 6897
2017
Q2 		$39K Sell
75
-2
-3% -$1.04K ﹤0.01% 6419
2017
Q1 		$43K Sell
77
-17
-18% -$9.49K ﹤0.01% 6336
2016
Q4 		$58K Sell
94
-8
-8% -$4.26K ﹤0.01% 6348
2016
Q3 		$62K Buy
102
+51
+100% +$32.9K ﹤0.01% 6403
2016
Q2 		$32K Buy
+51
New +$37.7K ﹤0.01% 6574
2014
Q4 		– Sell
-8
Closed -$15K – 7344
2014
Q3 		$15K Sell
8
-2
-20% -$4.18K ﹤0.01% 7019
2014
Q2 		$22K Buy
+10
New +$23.3K ﹤0.01% 6865

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Goldman Sachs's ORKA Position: Q2 2026 in Review

Goldman Sachs reduced its Oruka Therapeutics (ORKA) stake by 27% in Q2 2026, selling an estimated $4.48M and leaving 179,439 shares worth $17.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2799.

Goldman Sachs first reported a position in ORKA in Q2 2014 and has held it in 15 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Goldman Sachs held 179,439 shares of Oruka Therapeutics worth $17.1M as of Q2 2026.
  • Goldman Sachs sold 67,272 Oruka Therapeutics shares in Q2 2026, an estimated $4.48M.
  • Oruka Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2799 holding.
  • Goldman Sachs first reported a position in Oruka Therapeutics in Q2 2014 and has held it in 15 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.